GlassScriptPhysician profile
Jason Shaver
NPI 1013231950
$5,037.34
in general payments reported to CMS, 2019-2025
34 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.03 · 2022: $772 · 2023: $1,194 · 2024: $1,454 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.13 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $992.79 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $824.52 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Grifols USA, LLC | $283.78 | 2022-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $264.48 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $224.49 | 2022-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $222.87 | 2022-2025 | |
| Csl Behring | $179.63 | 2022-2025 | Kcentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.87 | 2022-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $158.83 | 2022-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $142.29 | 2024-2025 | Arikayce |
| Abbvie INC. | $138.44 | 2022-2025 | |
| Mylan Specialty L.P. | $132.76 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $124.60 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $108.54 | 2023-2025 | Zerbaxa, Recarbrio |
| Pfizer INC. | $103.16 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $101.70 | 2023-2025 | Xolair |
| Mallinckrodt Hospital Products INC. | $92.04 | 2022-2025 | Acthar |
| Viatris Specialty LLC | $83.94 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $83.67 | 2022-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $81.83 | 2024-2025 | |
| Amgen INC. | $66.73 | 2022-2024 | Tezspire |
| Idorsia Pharmaceuticals US INC | $66.09 | 2023-2024 | Quviviq |
| Baxter Healthcare | $64.93 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Avadel Cns Pharmaceuticals, LLC | $51.62 | 2023-2024 | Lumryz |
| Lilly USA, LLC | $50.17 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $43.89 | 2025 | Glassia |
| Ani Pharmaceuticals, INC. | $39.53 | 2022 | |
| Verona Pharma, INC. | $29.63 | 2025 | Ohtuvayre |
| Electromed, INC. | $27.59 | 2023-2024 | Smartvest |
| Shionogi INC | $21.28 | 2024 | Fetroja |
| Zoll Respicardia, INC. | $20.04 | 2023 | Remede System |
| Philips North America LLC | $18.50 | 2025 | Vest Therapy Und |
| Daiichi Sankyo INC. | $17.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.